Box C/D Small Nucleolar RNA (snoRNA) U60 Regulates Intracellular Cholesterol Trafficking

Katrina A. Brandis, Sarah Gale, Sarah Jinn, Stephen J. Langmade, Nicole Dudley-Rucker, Hui Jiang, Rohini Sidhu, Aileen Ren, Anna Goldberg, Jean E. Schaffer, and Daniel S. Ory

From the Diabetic Cardiovascular Disease Center, Washington University School of Medicine, St. Louis, Missouri 63110

Background: The mechanisms regulating internalization of plasma membrane cholesterol in mammalian cells are not well understood.

Results: A cell line haploinsufficient for U60 snoRNA expression exhibits impaired plasma membrane to ER cholesterol trafficking and increased de novo cholesterol synthesis.

Conclusion: U60 snoRNA expression regulates cholesterol homeostasis by affecting internalization of plasma membrane cholesterol.

Significance: This is the first study to implicate a snoRNA in regulation of cholesterol homeostasis.

Mobilization of plasma membrane (PM) cholesterol to the endoplasmic reticulum is essential for cellular cholesterol homeostasis. The mechanisms regulating this retrograde, intermembrane cholesterol transfer are not well understood. Because mutant cells with defects in PM to endoplasmic reticulum cholesterol trafficking can be isolated on the basis of resistance to amphotericin B, we conducted an amphotericin B loss-of-function screen in Chinese hamster ovary (CHO) cells using insertional mutagenesis to identify genes that regulate this trafficking mechanism. Mutant line A1 displayed reduced cholesterol ester formation from PM-derived cholesterol and increased de novo cholesterol synthesis, indicating a deficiency in retrograde cholesterol transport. Genotypic analysis revealed that the A1 cell line contained one disrupted allele of the U60 small nucleolar RNA (snoRNA) host gene, resulting in haploinsufficiency of the box C/D snoRNA U60. Complementation and mutational studies revealed the U60 snoRNA to be the essential feature from this locus that affects cholesterol trafficking. Lack of alteration in predicted U60-mediated site-directed methylation of 28 S rRNA in the A1 mutant suggests that the U60 snoRNA modulates cholesterol trafficking by a mechanism that is independent of this canonical function. Our study adds to a growing body of evidence for participation of small noncoding RNAs in cholesterol homeostasis and is the first to implicate a snoRNA in this cellular function.

Cholesterol homeostasis serves to maintain optimal sterol content in mammalian cell membranes. In addition to contributing to the structural properties of the phospholipid bilayer, cholesterol is necessary to maintain plasma membrane (PM) lipid raft structures that house a multitude of integral and membrane-associated proteins and complexes that are critical for cellular function. Cellular cholesterol originates from two sources: low density lipoprotein (LDL)-associated cholesterol and de novo synthesis, although uptake of cholesterol through the LDL-receptor pathway is the most quantitatively important of these in mammalian cells under physiological conditions.

The itinerary of LDL-derived cholesterol is well established. Following internalization via the LDL receptor, LDL particles are trafficked to a late endocytic compartment where esters are hydrolyzed by acid lipase to free cholesterol and subsequently released from endolysosomes via the concerted actions of the Niemann-Pick C1 (NPC1)/Niemann-Pick C2 (NPC2) proteins. Most of this cholesterol is then transported to the PM with a minor amount transported directly to the endoplasmic reticulum (ER), Golgi, and mitochondria (1–3). In mammalian cells, the PM is estimated to contain 60–90% of total cellular cholesterol, whereas the ER contains as little as 0.1–2% (4). This steep gradient is maintained despite a brisk flow of cholesterol between these compartments (5). It is hypothesized that this pathway provides for “sampling” of cellular cholesterol levels in the ER, where the sterol-sensing SREBP cleavage-activating protein (SCAP) senses ER cholesterol levels that govern maturation of the sterol regulatory element-binding protein (SREBP) transcription factors, master regulators of genes involved in cholesterol synthesis and uptake.

A number of stimuli influence PM to ER retrograde cholesterol transport, including alteration of PM phospholipid content, insertion of membrane-disordering oxysterols, disruption of lipid rafts, and increasing bulk PM cholesterol content (6–8). Although the mechanism by which cholesterol is transported between the PM and ER membranes is not yet established, it is thought to be nonvesicular in nature (9). Consistent with a protein-mediated mechanism, knockdown of ORP1/2, members of

*This work was supported, in whole or in part, by National Institutes of Health Grants HL1033001 (to D. S. O.) and DK064989 (to J. E. S.).
This article contains supplemental Fig. 1 and Table 1.
1 Supported by National Institutes of Health Training Grant T32 HL07275.
2 To whom correspondence should be addressed: Diabetic Cardiovascular Disease Center, Washington University School of Medicine, Box 8086, 660 S. Euclid Ave., St. Louis, MO 63110. Tel.: 314-747-0677; Fax: 314-747-0264, E-mail: dory@wustl.edu.
3 The abbreviations used are: PM, plasma membrane; snoRNA, small nucleolar RNA; snoRNP, small nucleolar ribonucleoprotein; ER, endoplasmic reticulum; HDL, high density lipoprotein; LDL, low density lipoprotein; CholR, cholesterol reductase; NPC1, Niemann-Pick C1; NPC2, Niemann-Pick C2; NPC, Niemann-Pick; SREBP, sterol regulatory element-binding protein; ORP, oxysterol transfer protein; ACAT, acyl-coenzyme A:cholesterol acyltransferase; LPD, lipoprotein-depleted; PC, phosphatidylcholine; LPC, lysophosphatidylcholine; DMSO, dimethyl sulfoxide; FACS, fluorescent activated cell sorting; qPCR, quantitative PCR; ASE, antisense element.
SNORD60 in Cellular Cholesterol Trafficking

the oxyysterol binding protein family known to participate in intermembrane trafficking of sterols, reduced PM to ER cholesterol trafficking in HeLa cells (10). Likewise, the STARD4 protein has been implicated in intermembrane transfer of cholesterol between the endocytic recycling compartment and ER (11). On the other hand, cholesterol transfer has been shown to occur between closely apposed PM and ER membrane contact sites (12). Although both types of mechanisms may contribute to total retrograde cholesterol transport, their respective contributions under physiologic conditions is uncertain.

In a previous genetic screen, cells selected for resistance to amphotericin B, a cholesterol-dependent pore-forming toxin, isolated mutants from two complementation groups: those harboring defects in transport of cholesterol from the lysosome to the PM and those with defective PM to ER trafficking (13–15). Subsequent studies revealed that former mutants (2-2 and 4-4) resulted from disruption of the NPC1 gene (16), whereas the genetic defect in the latter mutant (3–6) remains uncharacterized, highlighting the challenge of identification of the mutagenized loci in these ethyl methanesulfonate-generated cell lines (15). Together with molecular simulations and model membrane studies that suggest the availability of cholesterol to trafficking mechanisms may first be determined by its local membrane lipid environment (6, 17, 18), these data raise the possibility that amphotericin B resistance could arise from changes in PM phospholipid content that alter PM cholesterol levels or organization (15). To further delineate the genes involved in the internalization of PM cholesterol, we performed a loss-of-function screen in Chinese hamster ovary (CHO) cells mutagenized with the ROSAβGEO promoter trap virus to isolate mutants resistant to the amphotericin B cholesterol binding toxin (19, 20). Herein, we describe a CHO cell mutant in which a genetic disruption of the U60 small nucleolar RNA (snRNA) host gene impairs PM to ER retrograde cholesterol transport.

**EXPERIMENTAL PROCEDURES**

**DNA Constructs**—For expression of the genomic mouse U60snhg locus, the genomic sequence, including 2 kb of upstream promoter sequence and 1 kb of downstream sequence, was cloned into the pSilencer 4.1-CMV Hygro vector, with CMV and other vector expression sequences removed. A U60snhg locus, the genomic sequence, including 2 kb of upstream sequence, was cloned into the pSilencer 4.1-CMV Hygro vector, with expression driven by the CMV promoter.

**Cell Culture**—Chinese hamster ovary-K1 (CHO-K1) cells (CRL-9618) were obtained from ATCC. CHO-K1 Cells were maintained in monolayer culture at 37 °C with 5% CO2. All CHO-derived cell lines were maintained in normal medium consisting of 1:1 Dulbecco’s modified Eagle’s medium:Ham’s F-12, 5% (v/v) fetal calf serum, 2 mM glutamine, 50 units/ml penicillin, 50 μg/ml streptomycin. NIH 3T3 cells (ATCC CRL 1658) were grown in DMEM containing 10% (v/v) calf serum (Sigma) and 50 units/ml penicillin and streptomycin.

**Amphotericin B Loss-of-Function Screen**—A stable pool of ROSAβGEO-transduced CHO cell mutants was generated as described previously (19). This pool of mutants was grown for 24 h in cholesterol starvation medium consisting of 1:1 DMEM: Ham’s F-12 with 1% (v/v) lipoprotein-deficient serum (LPDS), 2 mM glutamine, 50 units/ml penicillin, 50 μg/ml streptomycin, 20 μM lovastatin, and 50 μM mevalonate. Final concentration of DMSO during selection was <1%. Cells were re-fed with 9 μg/ml LDL in 5% LPDS for 24 h. Cells were then treated with 175 μg/ml amphotericin B in DMSO for 6 h and then replaced with normal medium. After recovery, the starvation, LDL treatment, and amphotericin selection were repeated. The surviving mutant CHO cell population was plated at a limiting dilution to select stable amphotericin B-resistant clones.

**Basal PM Cholesterol Esterification Assay**—[3H]Cholesterol (1 mCi/ml) was obtained from PerkinElmer (NET 139). [3H]Cholesteryl ester formation was assessed as described previously (2). Cells were split from confluency by one-third and grown for 24 h. These cells were then seeded at 2.5 × 104 per well in a 6-well dish for 24 h. Medium was changed to 5% LPDS for 24 h. Cells were then pulsed for a given time with 1 μCi/ml [3H]cholesterol in 1 ml of 5% LPDS media and were treated with either 1 μM 25-hydroxycholesterol in ethanol (final ethanol concentration, 0.01%) or 50 μM 2-hydroxypropyl-β-cyclodextrin-cholesterol where indicated. Cyclodextrin:cholesterol complexes were prepared as described in Lange et al. (21). Cells were washed with cold Tris-buffered saline (TBS) for 10 min at 4 °C. Lipids were extracted from each well in 3 ml of 3:2 hexane:isopropyl alcohol and dried under nitrogen. [14C]Cholesteryl oleate was added to lipid extracts as a recovery standard. Cholesterol esters (CE) were separated from cholesterol by thin layer chromatography (TLC) in a 130:30:2 heptane/ethyl ether/acetic acid solvent using 100 μg of cholesterol and 30 μg of CE as carriers, respectively, and visualized by iodine. The percentage of recovery of [3H]CE was assessed by recovery of [14C]cholesteryl oleate. [3H]Cholesterol esterification was measured as a ratio of recovery-normalized [3H]CE to total [3H]cholesterol.

**ACAT Activity Assays**—Acyl-CoA:cholesterol acyltransferase (ACAT) activity was carried out as described previously (4). Cells were seeded at 5 × 105 in 10-cm plates overnight. Medium was changed to 5% LPDS for 24 h. Isolated microsomes were resuspended in 60 μl of 0.1 M potassium phosphate (pH 7.4)/1 mM DTT and supplemented with 1 mg of fatty acid-free BSA in 0.1 M K-phosphate/DTT buffer. For the ACAT activity assay, 100 μl of cholesterol/Triton WR-1339 solution (20 μg of cholesterol, 60 μg of Triton-WR) was added to provide excess cholesterol. 20 μl of 250 μM [14C]Oleoyl-CoA in 0.01 M K-phosphate was added to label CE formed by ACAT. ACAT inhibitor, CI-976 (gift from Warner-Lambert), dissolved in ethanol, was added to a 2 μM final concentration where described. Esterification was carried out at 37 °C for 15 min for ACAT activity and quenched with 4 ml of 2:1 chloroform/methanol. 800 μl of PBS was added to extract lipids, and organic phase was removed and dried down under nitrogen. CE were separated by TLC in the same manner as described above and counted by scintillation.

**Electron Microscopy**—Deep etch electron microscopy to assess plasma membrane-ER contact sites was performed in the Heuser laboratory (Washington University) as described (22). Cells were grown on coverslips and unroofed using a brief ultra-
sound pulse in an intracellular buffer (30 mM Hepes, pH 7.2, 70 mM KCL, 5 mM MgCl₂, and 3 mM EGTA). Samples were immediately fixed in buffer containing 4% paraformaldehyde or 2% glutaraldehyde. Coverslips were frozen, replicated, and imaged as described (22).

PM and ER Fractionations—Isolation of PM was carried out using the plasma membrane protein extraction kit per the manufacturer’s protocol (Abcam, Cambridge, MA). Briefly, cells were seeded at a density of 3 × 10⁵ per 10-cm plate and grown for 24 h in normal medium and then changed to medium containing 5% LPDS for 24 h. 50 plates were used for each fractionation. Cells were homogenized with 75 stokes in a Dounce homogenizer, and the postnuclear supernatant was spun at 10,000 × g to obtain total cellular membrane proteins. Membranes were then resuspended in the upper phase solution and extracted using the lower phase solution followed by centrifugation to pellet the PM. ER membranes were isolated as described previously (23). Equal protein amounts of each fraction were run by SDS-PAGE and assessed for purity by Western blotting with Na/K⁺ ATPase (sodium pump), protein disulfide isomerase, and prohibitin organelle markers for the PM, ER, and mitochondria, respectively.

Lipidomics—To membrane fractions, internal standards (either deuterated or incorporating odd chain fatty acyl species) were added, and lipid extraction was performed by the method of Bligh and Dyer (24). Liquid chromatography tandem mass spectrometry (LC-MS/MS) was used for lipid species quantification (25).

RACE—The exon sequence fused upstream of the ROSAβGEO cassette was identified by 5' RACE (SMART RACE cDNA amplification kit, Clontech) of total RNA extracted from the CHO A1 cell line, utilizing the known sequences of a 5’-ligated oligonucleotide and the ROSAβGEO transcript (see supplemental Table 1). The resulting sequenced 5' RACE product was then used to conduct 3' RACE using wild type (WT) CHO RNA to identify the remaining 3' exons in the disrupted locus. PCR was carried out using WT CHO or A1 genomic DNA as a template, with a forward primer specific to the 5' end of the RACE product and a reverse primer either specific to the 3' end of the RACE product to amplify the WT locus or specific to the middle of the ROSAβGEO provirus to amplify the disrupted locus.

Southern Blot—Genomic DNA from WT CHO and A1 cells were digested with XbaI, NotI, and BglII, run on a 1% agarose gel, and transferred to GeneScreen nylon membrane. A 32P end-labeled probe antisense to the ROSAβGEO sequence was used to probe for ROSAβGEO proviral integration.

Generation of U60-complemented Clones and U60 Knockdown Clones—The full-length U60snRNA mouse locus was amplified from genomic DNA. It contains 2 kb of upstream promoter sequence and 1 kb of sequence downstream of U60snRNA exon 2. The PCR product was amplified with primers containing NotI and Kpn1 sequences for cloning into the pSilencer 4.1 vector lacking CMV. To generate stable knockdown clones, an shRNA oligonucleotide (see supplemental Table 1) directed against the murine U60snRNA was cloned into a pSilencer 4.1-CMV Hygro vector (Ambion). The shRNA vector was transfected into NIH 3T3 cells. Cells were plated at limiting dilution and selected with hygromycin, and clonal cell lines (KD1 and KD2) were isolated.

Measurement of U60 snoRNA by qPCR—TRIzol-extracted RNA was reverse-transcribed with the SuperScript III kit (Invitrogen). U60 snoRNA was reverse-transcribed with a stem-loop primer with oligo(dT) reversed transcribed poly(A) RNAs. cDNAs were detected and amplified using SYBR Green master mix (Applied Biosciences) (see primer list in supplemental Table 1).

U60 snoRNA Immunoprecipitation—U60 snoRNA was in vitro transcribed from a short DNA oligonucleotide containing a 5’-T7 sequence and the mouse SNORD60 gene (Megascript T7 kit, Invitrogen). The in vitro transcription reaction was run on an 8 M urea 10% polyacrylamide gel. RNA products were visualized by ethidium bromide staining and excised for overnight elution. Eluted U60 was precipitated and end-labeled with 32P-biotin (RNA 3’ end biotinylation kit, Pierce). The efficiency of labeling was determined by dot blot.

3T3 mouse fibroblasts were seeded and cultured overnight at 5 × 10⁵ cells/10-cm plate. Cells were transfected with 5 pmol of Bio-U60 plus 8 μg of FLAG-protein DNA construct per plate using Lipofectamine Plus. Cells were lysed in TNEN (50 mM Tris, pH 8.0, 0.15 M NaCl, 2 mM EDTA, 0.5% Nonidet P-40, 1× Complete protease inhibitor cocktail, 1 mM PMSF) buffer plus Superserin 24 h after transfection, and postnuclear supernatant was used for FLAG immunoprecipitation using anti-FLAG beads (anti-FLAG M2 affinity gel, Sigma) (26). RNA was extracted from FLAG beads using TRIZol, and RNA was run on 4% native polyacrylamide gel, transferred to nylon membrane, and blotted for presence of biotin (chemiluminescent nucleic acid detection module, Pierce).

Measurement of Site-specific rRNA Methylation by Primer Extension qPCR—Detection of rRNA methylation was adapted from Belin et al. (27). RNA was extracted from yeast cells using the RiboPure-yeast kit (Ambion) or from CHO cell lines using TRIzol. 28 S and 18 S RNAs were separated from total RNA by agarose-gel electrophoresis, visualized by ethidium bromide staining, and isolated by gel extraction. One ng of RNA was used for reverse transcription (RT) by SuperScript III in the presence of either 1 μM or 1 mM dNTPs using reverse primer directed downstream of the methylation site. qPCR was carried out using SYBR Green master mix to detect RT extended primers using the primer set flanking methylation site (supplemental Table 1).

RESULTS

Amphotericin B Loss-of-Function Screen—To generate a pool of mutagenized CHO cells, we performed insertional mutagenesis using the ROSAβGEO retrovirus (19, 20). Transduction was optimized to achieve an average of one insertion per 20 genomes. The integrated provirus contains a β-galactosidase gene, a neomycin resistance gene, and a poly(A) signal with no upstream promoter sequence, thus only conferring antibiotic resistance and genetic disruption if integrated downstream of an active promoter and splice donor. G418 selection of transduced cells was used to generate a pool of stably mutagenized CHO cells. This pool of cells was subjected to amphotericin B/LDL selection twice, after which individual cell lines were...
isolated (Fig. 1A). At the amphotericin B and LDL concentrations used in the screen, nonmutagenized WT cells failed to survive the two rounds of selection, thus minimizing background. To select amphotericin B-resistant mutants that did not simply harbor defects in the egress of endolysosomal cholesterol (e.g. NPC1 mutants), only clones that displayed normal filipin staining patterns (28) were selected for further analysis.

The A1 Mutant Cell Line Has Reduced PM to ER Cholesterol Trafficking—To screen CHO mutants for altered rates of cholesterol transfer from the PM to internal membranes, we measured the availability of PM cholesterol for trafficking to the ER by determining the rate of esterification of cell surface cholesterol by ACAT. For these experiments, cells were grown in lipoprotein-deficient medium, pulsed with ethanolic [3H]cholesterol, which readily incorporates into the PM, and subsequently assayed for detection of [3H]CE. One of the cell lines, A1, consistently displayed a 50–60% decrease in basal [3H]CE formation over a 24-h time course when compared with WT cells (Fig. 1B). This was not due to a deficiency in ACAT activity in A1 as microsomes isolated from WT and A1 cells incubated with [14C]oleate and excess cholesterol displayed similar levels of [14C]CE formation (Fig. 1C). Because the cycling of cholesterol between the PM and ER is required for proper sensing of total cellular cholesterol levels by the ER-localized SREBP cleavage-activating protein (SCAP) and Insig sterol-sensing proteins, deficiency in PM to ER cholesterol trafficking in A1 cells would be expected to result in dysregulated cholesterol synthesis. Incorporation of [3H]acetate into de novo synthesized cholesterol was measured in WT and A1 cells over a time course. Under the same growth conditions used for the basal cholesterol esterification assay, the A1 cell line displayed a 2-fold increase in the rate of cholesterol synthesis when compared with WT cells (Fig. 1D). Together with the basal PM cholesterol esterification assay, these data suggest that A1 cells, when grown in the absence of exogenous LDL cholesterol, are deficient in cholesterol trafficking from the PM to the ER.

To determine whether altered expression of genes previously implicated in regulation of cholesterol homeostasis might be contributing to the cholesterol trafficking phenotype (7, 10, 11), we measured the mRNA abundance of cholesterol trafficking genes (caveolin 1, STARD4, ORP1S, and ORP2) and plasmalogen synthesis genes (DHAPAT and DHAPS) using hamster-
specific primers (supplemental Table 1) and qPCR. No differences were found between WT and A1 cells with respect to expression of these genes (not shown). Electron microscopy studies of WT and A1 cells were also performed but did not demonstrate differences in the density of PM-ER contact sites or in the morphology of PM caveolae (not shown).

Activation of PM Cholesterol Overcomes the Cholesterol Trafficking Defect in the A1 Mutant—The reduced PM to ER cholesterol trafficking in the A1 mutant could be a consequence of reduced PM cholesterol or altered membrane composition. In either event, reduced PM cholesterol activity, the tendency for cholesterol to leave the membrane, might be responsible for the trafficking defect. To test this, we treated cells with cholesterol-activating agents, 25-hydroxycholesterol or 2-hydroxypropyl-β-cyclodextrin-complexed cholesterol; both have been shown to stimulate esterification of PM-derived cholesterol by activating (i.e. stimulating the release) cholesterol in membranes (4).

[3H]CE formation was measured in WT and A1 cells treated with 25-hydroxycholesterol and 2-hydroxypropyl-β-cyclodextrin-complexed cholesterol, which stimulated esterification ~15–18-fold and ~150–200-fold above basal levels, respectively, in both cell lines. Interestingly, both treatments resulted in significantly greater [3H]CE formation in A1 when compared with WT cells (Fig. 2, A and B). The increased formation of [3H]CE demonstrates that not only is A1 PM cholesterol transfer to the ER intact under cholesterol-activating conditions, but cholesterol is actually transferred at a higher rate than in WT cells. These data would suggest that the A1 cholesterol trafficking defect does not result from PM cholesterol deficiency or defective cholesterol trafficking machinery.

A1 Cells Have Increased PM Phosphatidylcholine (LPC) Content—The dynamics of membrane-associated cholesterol are dependent on the composition of the resident lipid environment, in particular the phospholipid acyl chain composition (6, 29). To examine whether the A1 mutant has an altered cellular or PM lipidome that might affect movement of cholesterol within and between membranes, lipidomic analysis was performed on postnuclear supernatants and PM-enriched fractions from WT and A1 cells. Purity of PM fractions was assessed by detection of subcellular markers (Na/K+ ATPase, PM; protein disulfide isomerase, ER; and prohibitin, mitochondria) through Western blotting and showed similar enrichment for the PM markers and depletion of the ER and mitochondrial markers in both parental and mutant cells (Fig. 3A). Using LC-MS/MS, the whole cell lysates and PM fractions from WT and A1 cells were broadly surveyed for cholesterol, cholesteryl ester, ceramide, sphingomyelin, phosphatidylcholine (PC), phosphatidylethanolamine, phosphatidylinositol, phosphati-
dyglycerol, and lysophosphatidylcholine (LPC) species. Total LPC species were increased 1.5-fold (p < 0.05) in the A1 PM fraction (Fig. 3B). This was principally attributable to an increase in the most abundant LPC species (LPC16:0) (Fig. 3C) and was accompanied by an ~1.6-fold (p < 0.05) increase in total saturation of LPC acyl chains. No significant differences were observed between WT and A1 cells in the other lipid classes (supplemental Fig. 1), although there was a trend toward increased PC 16:0/16:0 in the A1 PM fraction (p = 0.07) with a 1.2-fold increase in total saturation of PC acyl chains (Fig. 3, D and E).

The A1 Cell Line Is Haploinsufficient for Expression of the U60 snoRNA Host Gene—To identify the disrupted gene causing the cholesterol trafficking defect in the A1 cell line, we used the ROSAβGEO insertion as a tag to identify the locus of integration. Southern analysis probing for the ROSAβGEO proviral sequence revealed that the A1 cell line contains only one ROSAβGEO insertion (Fig. 4A). A 5′ and 3′ RACE was conducted using RNA isolated from A1 to define the upstream exon sequence fused to the ROSAβGEO viral cassette and other exon sequences in the locus. BLAST analysis of the resulting 330-nucleotide RACE sequence against the mouse genome revealed no matching exon sequences (the hamster genome had not been sequenced at the time of this analysis). To confirm that the RACE sequence was produced from the locus of integration, PCR using forward and reverse primers designed to the 5′ and 3′ ends of the RACE sequence, respectively, was used to amplify the putative locus from WT and A1 genomic DNA. A single band was amplified from both WT and A1 templates. Using the same 5′ forward primer and a 3′ reverse primer designed to the ROSAβGEO cassette, a larger band was produced exclusively with A1 genomic template DNA, thus confirming that the RACE sequence corresponded to the locus disrupted by ROSAβGEO (Fig. 4B). That the smaller PCR product appeared using either WT or A1 template indicates that the A1 cell line also contains an intact WT locus and is likely to serve as a model of haploinsufficiency for the disrupted gene.

FIGURE 2. Cholesterol activation corrects the PM to ER cholesterol trafficking defect in the A1 cell line. A and B, cells were pulsed with [3H]cholesterol and co-treated with either 25-hydroxycholesterol (25-HC) (A) or 2-hydroxypropyl-β-cyclodextrin-complexed cholesterol (HPCD) (B). The percentage of cholesterol esterification was calculated after scintillation counting of [3H]CE and [3H]cholesterol. Data represent mean values ± S.E. from triplicate cultures.

A

B

Downloaded from http://www.jbc.org/ by guest on June 23, 2017
Because the initial RACE sequence did not contain significant homology to any known genome, these two PCR products were then sequenced to identify the locus of integration using other sequences of the gene and to determine the precise genomic locus at which ROSA/H9252 GEO integrated. BLAST analysis of these sequences revealed that the disrupted A1 locus was homologous to the mouse transcript 2610019E17Rik, also known as the U60 snoRNA host gene (U60snhg), which was identified by the highly conserved box C/D snoRNA, snordU60, within the intron of the gene.

Features of the U60snhg Locus and the U60 Box C/D snoRNA—U60snhg is comprised of two exons and one intron, generating an ~500-bp pre-mRNA transcript. The box C/D snoRNA U60 at the 5’ end of the U60snhg intron is the only region of significant sequence conservation in the gene (Fig. 4C). The exon-intron structure, however, is identical among all mammalian species. Additionally, the short promoter region (<500 bp) also contains areas of significant sequence homology, indicating that the U60snhg is likely to be similarly regulated at the transcriptional level among mammals. The U60snhg exon sequences in the mouse, rat, and human genomes contain no open reading frames, whereas the hamster sequence contains two predicted products of 36 and 44 amino acids that are not evolutionarily conserved, suggesting that U60snhg is, indeed, a noncoding RNA. Taking these data together, it seems likely that the main function of U60snhg is to serve as a transcriptional unit to generate the intron lariat housing U60 snoRNA for processing into a mature snoRNA.

The U60 snoRNA belongs to the box C/D class of snoRNAs. Similar to canonical box C/D snoRNAs, U60 contains box C (UGAUGA) and box D (CUGA) sequence elements on the 5’ and 3’ ends, respectively, with lesser conserved canonical internal box C’ and box D’ elements as well (Fig. 4C). The C and D box elements are necessary for the binding of the core proteins that recruit the fibrillarin methyltransferase to the snoRNP. C/D snoRNPs can then mediate 2’-O-methylation of rRNA nucleotides by bringing fibrillarin in close proximity to the targeted site via complementary base pairing between the snoRNA antisense element (ASE) and the rRNA sequence containing the nucleotide to be modified. U60 is thus predicted to base pair...
with 28 S rRNA via its ASE upstream of the D’ box and is thought to perform the 2'-O-methylation identified at nucleotide G4340.

Sequencing of the ROSAβGEO PCR product obtained using A1 genomic DNA as template revealed that integration of ROSAβGEO into this locus occurred within the U60snhg intron, downstream of the snoRNA and upstream of the branch point adenosine. It has been shown that the spacing between the 3’ end of intronic box C/D snoRNAs and the branch point is important for proper processing of such snoRNAs from intron lariat (30). Thus, improper processing of U60 at this disrupted locus in A1 would be expected to contribute to decreased levels of the mature U60 snoRNA.

The A1 Cell Line Is Haploinsufficient for U60 snoRNA Expression—RT-qPCR was used to detect mature U60 snoRNA levels. To ensure that the U60snhg pre-mRNA was not amplified in this method, a stem-loop primer for reverse transcription was designed to prime to the last 6 bp of the 3’ end of the processed U60 snoRNA. For qPCR, a conventional forward primer was directed to the 5’ end of U60 with a reverse primer directed to the denatured stem-loop primer. When compared with WT cells, a 50% reduction in mature U60 snoRNA levels was observed in A1 (Fig. 5A). Interestingly, growth of WT and A1 cells in lipoprotein-deficient serum appeared to suppress U60 snoRNA expression, suggesting that regulation of U60 snoRNA expression is responsive to cellular cholesterol content. As expected, disruption of one U60snhg allele in the A1 mutant results in U60 snoRNA haploinsufficiency.

The Cholesterol Trafficking Defect in A1 Mutant Is Abrogated by Complementation with U60 snoRNA—To determine whether reduced U60 snoRNA expression causes the A1 cell line cholesterol trafficking phenotype, A1 clones stably expressing the full-length mouse U60snhg genomic locus (A1-WT) were generated and screened for complementation by the basal PM cholesterol esterification assay. To express the U60 snoRNA at endogenous levels, 2 kb of upstream sequence was...
included as a promoter. Clones expressing the U60 snoRNA at levels greater than or equal to WT levels were chosen for complementation analysis (Fig. 5C). In two A1-WT clones, cholesterol esterification was restored to WT levels (Fig. 5D). To assess whether the U60 snoRNA or the U60snhg mRNA is the critical transcriptional unit in the locus, clones stably expressing the U60snhg locus in which the D' box or a portion of the ASE of the U60 snoRNA were mutated to adenines (A1-D box or A1-ASE, Fig. 5B) and assayed for esterification. The D' box is important for proper C/D snoRNP formation, whereas the ASE sequence, which is complementary to the U60 RNA target, 28S rRNA, is predicted to direct site-specific methylation. None of the A1-D box or A1-ASE clones displayed cholesterol esterification levels significantly different from the A1 cell line, despite

FIGURE 5. Reduced U60 snoRNA expression causes reduced PM to ER cholesterol trafficking in the A1 cell line. A, U60 snoRNA expression was measured by qPCR using a 3'-U60 specific stem-loop primer for RT and normalized to 36B4 mRNA. Data are represented as mean ± S.E. from three separate experiments. B, mouse U60snhg expression constructs WT, mutASE, and mutD used for complementation of A1 cell line in C. Capital letters indicate nucleotides conserved among mammalian species. C, stable cell lines were generated after transfection of A1 cells with indicated constructs and selection with hygromycin. Mouse U60 snoRNA expression was measured as in A. *, p < 0.05, **, p < 0.01 for A1 versus WT and all other clones. ref units, relative units. D, PM cholesterol esterification assay. Cells were pulsed with [3H]cholesterol for 4 h. Data represent mean esterification ± S.E., normalized to WT, from three separate experiments. E, expression of mouse U60snhg mRNA was measured by qPCR in complemented clones, normalized to 36B4 mRNA. Data represent mean values ± S.E. from triplicate cultures. Data values are not significantly different.
Having WT levels of U60 snoRNA expression. Importantly, the clones stably expressing these mutants showed equal U60snhg mRNA expression, ensuring that lack of complementation was not due to reduced expression of other elements in this locus (Fig. 5D). Taken together, these data indicate that not only is the U60 snoRNA the relevant transcriptional unit of the locus in affecting PM to ER cholesterol trafficking, but the data also indicate that the D box and the antisense element are necessary for this function of U60.

**U60 snoRNA Knockdown Recapitulates Cholesterol Trafficking Defect in 3T3 Mouse Fibroblasts**—To determine whether reduced U60 expression can affect PM cholesterol trafficking in other cell types, we knocked down the U60 snoRNA in mouse 3T3 fibroblasts. In two clones stably expressing an shRNA directed to knock down U60, reduced U60 expression caused a decrease in basal PM cholesterol esterification (Fig. 6). Thus, recapitulation of the A1 cell line cholesterol trafficking defect in another organism and cell line confirms that the U60 snoRNA likely functions to affect PM cholesterol trafficking in mammalian cells.

**The U60 snoRNA Associates with Canonical C/D snoRNP Core Proteins**—As a putative box C/D snoRNP, we first sought to verify that U60 is capable of forming a C/D snoRNP. To accomplish this, RNA immunoprecipitation was used to detecting a 3′ end biotin-labeled U60 snoRNA (BioU60) within C/D snoRNP immunoprecipitates. FLAG-Nop56 or FLAG-Fibrillarin constructs were co-expressed with BioU60 in 3T3 fibroblasts. Cells were lysed to perform FLAG immunoprecipitation from which RNA was extracted and probed for BioU60 content. BioU60 was shown to co-immunoprecipitate with both fibrillarin and Nop56 proteins (Fig. 7A), indicating that the U60 snoRNA can be reconstituted into a C/D snoRNP in situ and is likely to function as a canonical box C/D snoRNA.

**Haploinsufficiency of the U60 snoRNA Does Not Cause Reduced 28 S rRNA G4340 Methylation**—Although the methylation of ribosomal RNA has not been demonstrated to specifically affect cholesterol trafficking, we considered that decreased U60 expression could cause reduced G4340 methylation in the A1 cell line, which in turn might be responsible for the cholesterol trafficking phenotype. To test this, primer extension was used in conjunction with qPCR (27). In this method, RT is performed using rRNA as a template, with a reverse primer directed 50–100 bp downstream of the methylation site of interest. When carried out with low dNTP concentrations, the transcriptase will stall at methylated nucleotides. The extended primers are then detected by traditional qPCR methods, using a primer set directly flanking the methylation site. Increased levels of fully extended primer measured by qPCR, therefore, indicate decreased methylation. As a positive control, rRNA was isolated from WT and Δsnr40 knock-out yeast strains, the latter containing no box C/D snr40 snoRNA and incapable of rRNA methylation at G1267 (31). When using Δsnr40 rRNA as a template for RT with low dNTPs, we observed that the reaction produced more extended primer than WT rRNA template (Fig. 7B). We then probed for G4340 methylation using WT and A1 28S rRNA as template. qPCR detection of the RT-extended primer was equal in both samples (Fig. 7C). Although these data do not specifically address whether U60, in fact, methylates G4340, it does indicate that the methylation status of its only predicted target site is not affected by U60 haploinsufficiency in the A1 cell line. These data support the conclusion that the A1 mutant phenotype is not caused by defective rRNA methylation, and instead U60 acts by a noncanonical mechanism to affect cholesterol trafficking.

**DISCUSSION**

In the present study, we have identified a novel pathway linking a box C/D snoRNA to cholesterol homeostasis. We show that haploinsufficiency of the U60 snoRNA resulted in decreased PM to ER cholesterol trafficking, as measured by reduced PM cholesterol esterification and increased de novo cholesterol synthesis. This trafficking defect was overcome by complementation with the mouse U60snhg locus, whereas point mutations in the snoRNA sequence itself abrogated the complementation with this locus. These findings not only
SNORD60 in Cellular Cholesterol Trafficking

Implicate the snoRNA as the element of the locus that affects cholesterol trafficking, but also indicate that the regions within the snoRNA targeted for mutagenesis are necessary for this role of the U60 snoRNA. In demonstrating the ability of U60 to bind canonical C/D snoRNP core proteins, we found that U60 site-specific methylation was not deficient in the U60 haploinsufficient A1 cell line. Our findings demonstrate an unexpected role for the U60 snoRNA in regulation of intracellular cholesterol trafficking in a manner beyond its predicted canonical function.

Our studies suggest that the cholesterol trafficking defect in the amphotericin B-resistant A1 cell line is not simply a result of PM cholesterol deficiency as lipidomic analysis indicated normal PM cholesterol content and activation of PM cholesterol led to higher rates of cholesterol esterification than even WT cells. Instead, we speculate that under basal conditions, reduced propensity of cholesterol to leave the PM may responsible for the reduced PM cholesterol esterification. The cholesterol activation hypothesis (6) posits that the tendency of PM cholesterol to become more exposed at the aqueous-membrane interface and thereby increase accessibility to extramembrane acceptors is dependent on the lipid composition of the membrane. Increased saturation of PM phospholipid acyl chains could account for increased PM cholesterol retention: the saturated acyl chains interacting more strongly with cholesterol and positioning cholesterol closer to the bilayer center, thereby shielding cholesterol’s hydroxyl group from interaction with extracellular membrane acceptors (6, 23, 29, 32). How reduced U60 expression might specifically alter the PM lipid environment will require further understanding of the noncanonical functions of the U60 snoRNA.

Although box C/D snoRNAs have previously been shown to mediate rRNA methylation in eukaryotic cells (31), much of this analysis has been conducted in lower eukaryotes that do not contain a highly conserved U60snhg homolog with requisite box C and box D snoRNA elements or with similar exon-intron structure (Xenopus laevis, Gallus gallus, lizards). Although rRNA methylation may be the sole function of the box C/D snoRNAs expressed in these lower organisms, the conservation of mammalian U60 supports the notion that it may have additional, unique function(s) in higher organisms. Recently, another forward genetics screen conducted by our laboratory designed to identify genes involved in lipotoxicity produced a mutant CHO cell line haploinsufficient for the four box C/D snoRNAs derived from the introns of the rpl13a locus (33). Similar to our current findings, this study demonstrated that reduced expression of the U32, U33, and U35 snoRNAs did not result in deficient rRNA methylation at the predicted nucleotides. Together with the current study, these findings suggest that haploinsufficiency of these snoRNAs is sufficient to achieve normal levels of rRNA methylation, yet renders the cells either resistant to metabolic stress, in the case of the rpl13a snoRNAs, or defective in cholesterol trafficking, in the case of the U60 snoRNA.

Indeed, a growing number of box C/D snoRNAs have been shown in recent studies to exhibit noncanonical functions, including serving as substrates for processing into smaller, microRNA-like species and targeting pre-mRNAs in ways that impact splicing (34, 35). A U60-derived microRNA-sized species (the first 21–22 nucleotides of the 5’ end of the snoRNA) is present in deep sequencing databases and was shown to be well represented in skin tissue (36). It seems unlikely, however, that this portion of the U60 snoRNA possesses microRNA function as the alignment of this sequence across mammalian species reveals poor conservation, and Custom TargetScan analysis reveals no common mRNA-3’-UTR targets across species. Abundance of this short sequence may possibly reflect a long-lived degradation product. As with other snoRNA roles, it is likely that U60 exerts its effects on another RNA(s) via an RNA-RNA complementarity. It is probable that U60 utilizes its highly conserved antisense element for such a function because we found this sequence to be required to support normal cholesterol trafficking. Future studies will focus on identification of such putative RNA targets.

In addition to the classical transcriptional mechanisms that regulate cholesterol levels, another class of noncoding RNAs has recently been demonstrated to function at several levels of cholesterol homeostasis. miR-33 has been shown to regulate ABCA1, ABCG1, and NPC1 transcripts via 3’-UTR targeting, whereas the levels of miR-33 itself are also responsive to cellular cholesterol levels (37–39). These studies have established precedence for the role of noncoding RNAs in cholesterol biology, and we hypothesize that U60 may directly interact with other RNAs that play a role in cholesterol metabolism. In support of this notion, lowering intracellular cholesterol levels reduced U60 snoRNA expression, suggesting that either U60 expression or its stability is responsive to cellular cholesterol status. Moreover, the U60snhg promoter has been shown to be occupied by SREBP1 and its co-regulator NFY in HepG2 cells, indicating a potential for regulation by a cholesterol-responsive transcriptional program (40). Although most classical cholesterol-responsive genes are known to be transcriptionally activated under low cholesterol conditions, SREBP has also been demonstrated to transcriptionally repress genes involved in lipid catabolism, such as cholesterol 7α-hydroxylase (41). Beyond transcriptional and classical microRNA-mediated mechanisms, our study identifies snoRNAs as a new class of noncoding RNAs that contribute to regulation of cholesterol homeostasis.

Acknowledgments—We thank Robyn Roth and John Heuser for assistance with electron microscopy experiments. Mass spectrometry analyses were performed in the Metabolomics Facility at Washington University (National Institutes of Health Grant P30 DK020579).

REFERENCES


SNORD60 in Cellular Cholesterol Trafficking

Box C/D Small Nucleolar RNA (snoRNA) U60 Regulates Intracellular Cholesterol Trafficking

Katrina A. Brandis, Sarah Gale, Sarah Jinn, Stephen J. Langmade, Nicole Dudley-Rucker, Hui Jiang, Rohini Sidhu, Aileen Ren, Anna Goldberg, Jean E. Schaffer and Daniel S. Ory

J. Biol. Chem. 2013, 288:35703-35713.
doi: 10.1074/jbc.M113.488577 originally published online October 30, 2013

Access the most updated version of this article at doi: 10.1074/jbc.M113.488577

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2013/10/30/M113.488577.DC1

This article cites 41 references, 28 of which can be accessed free at
http://www.jbc.org/content/288/50/35703.full.html#ref-list-1